|
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | “My business model when I took over in 2017 was to outsource everything.” That’s as clear as it gets from a biotech CEO. Amit Kumar cuts to the chase during our conversation centered on the newly announced relationship between his company, Anixa Biosciences, and Cytovance Biologics, a U.S.-based CDMO. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Open-Label Study Assessing Relative And Absolute Bioavailability | White Paper | By Andy Sykes, Helena Engman, Nigel Taylor, et al., Quotient Sciences | Consistent absorption across different formulations and dietary conditions ensures stable therapeutic exposure. This flexibility simplifies patient dosing schedules and supports manufacturing transitions. |
|
|
|
| Why Lower Endotoxin Levels Matter | Article | By Haley Johnson, West Pharmaceutical Services, Inc. | Strengthen patient safety and regulatory compliance with comprehensive endotoxin control strategies designed to support the evolving demands of injectable and advanced pharmaceutical products. |
|
|
| Overcoming Product Instability And Improving Yield | Case Study | Grace Fine Chemical Manufacturing Services | Early identification of hidden product instability enabled rapid process adjustments, improving yield and keeping a preclinical toxicology program on track despite challenging reaction conditions. |
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
